Evaluation of the cost-effectiveness of evolocumab in the FOURIER study: a Canadian analysis

Todd C. Lee; Mohammed Kaouache; Steven A. Grover

doi:10.9778/cmajo.20180011

Research

Evaluation of the cost-effectiveness of evolocumab in the FOURIER study: a Canadian analysis

Todd C. Lee, Mohammed Kaouache and Steven A. Grover

April 05, 2018 6 (2) E162-E167; DOI: https://doi.org/10.9778/cmajo.20180011

Todd C. Lee

Division of General Internal Medicine (Lee, Grover), Department of Medicine, McGill University; Clinical Practice Assessment Unit (Lee), McGill University Health Centre, Montréal, Que.; Department of General Sciences (Kaouache), Prince Sultan University, Riyadh, Kingdom of Saudi Arabia; Centre for the Analysis of Cost-Effective Care (Grover), Montreal General Hospital, Montréal, Que.

MD MPH

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Mohammed Kaouache

PhD

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Steven A. Grover

MD MPA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Tables
Related Content
Responses
Metrics
PDF

Jump to comment:

No Responses have been published for this article.

PreviousNext

In this issue

Vol. 6, Issue 2

1 Apr 2018

Table of Contents
Index by author

Article tools

Respond to this article

Download PDF

Article Alerts

User Name *

Password *

To sign up for email alerts or to access your current email alerts, enter your email address below:

Email *

Email Article

Thank you for your interest in spreading the word on CMAJ Open.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Evaluation of the cost-effectiveness of evolocumab in the FOURIER study: a Canadian analysis

Message Subject (Your Name) has sent you a message from CMAJ Open

Message Body (Your Name) thought you would like to see the CMAJ Open web site.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

Evaluation of the cost-effectiveness of evolocumab in the FOURIER study: a Canadian analysis

Todd C. Lee, Mohammed Kaouache, Steven A. Grover

Apr 2018, 6 (2) E162-E167; DOI: 10.9778/cmajo.20180011

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Evaluation of the cost-effectiveness of evolocumab in the FOURIER study: a Canadian analysis

Todd C. Lee, Mohammed Kaouache, Steven A. Grover

Apr 2018, 6 (2) E162-E167; DOI: 10.9778/cmajo.20180011

Share This Article:

Tweet Widget
Facebook Like

PubMed
Google Scholar

Cited By...

No citing articles found.

Google Scholar

Collections

Clinical
- Cardiovascular Medicine
  - Drugs: cardiovascular system
  - Other cardiovascular medicine

Main menu

User menu

Search

Evaluation of the cost-effectiveness of evolocumab in the FOURIER study: a Canadian analysis

Jump to comment:

In this issue

Article tools

Citation Manager Formats

Related Articles

Cited By...

Similar Articles

Collections

Content

About